📝 Beryl Drugs Ltd — results explained
Quarter ended June 2026 (Q1 FY27)
Beryl Drugs Ltd reported revenue of ₹8 crore for the quarter ended June 2026 (Q1 FY27), up 56.7% from ₹5 crore in the same quarter last year, and up 38.3% sequentially over the March 2026 quarter.
Net profit rose 1004.0% year-on-year to ₹0 crore, from ₹0 crore. Earnings per share (EPS) came in at ₹0.44.
Operating profit stood at ₹1 crore — an operating margin (OPM) of 8.6%, compared with 11.4% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, Beryl Drugs Ltd posted revenue of ₹19 crore, a decline of 14.4% over FY25, with a net profit of ₹0 crore (down 27.6% year-on-year).
On a trailing-twelve-month (TTM) basis, revenue stands at ₹22 crore with a net profit of ₹1 crore.
Valuation snapshot
At the current price of ₹24.36, 524606 has a market capitalisation of ₹12 crore and a trailing P/E of about 20.0.
Within the Pharmaceuticals industry, it is the 25th-largest of the 82 companies we track by market value.
Shareholding pattern
As of Jun 2026, promoters held 27.82%, public shareholders 72.19% of Beryl Drugs Ltd.
Promoter holding rose from 27.48% to 27.82% over the latest period.